LRIG1 and autoimmune disease: When the Treg cell-stimulating mAb specific to Lrig1 is administered to patients with autoimmune disease, there is a possibility that the antibody binds to LRIG1+ cells, such as epithelial or intestinal stem cells in other tissues and may affect the proliferation status of the cells.